Generation Bio
We have no price for Generation Bio since 10 February 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Generation Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Generation Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Generation Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $5.25
- Range
- $5.00 – $5.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -3.20 | -5.50 | +41.9% |
| Nov 5, 2025 | -0.82 | -3.18 | +74.2% |
| Aug 12, 2025 | -3.12 | -2.80 | −11.4% |
| May 7, 2025 | -2.20 | -2.50 | +12.0% |
| Mar 13, 2025 | -0.32 | -0.28 | −14.3% |
| Nov 6, 2024 | -0.23 | -0.28 | +17.9% |
| Aug 7, 2024 | -0.31 | -0.27 | −14.8% |
| May 13, 2024 | -1.12 | -0.36 | −211.1% |
News
I’m 17 and will be a first-generation college student. Is law school worth being $200,000 in debt?MarketWatch · Nov 12, 2026Next Generation Computing - Global Strategic Business Report 2026-2032: Capitalize on 19% CAGR, Featuring Intelligence on NVIDIA, IBM, Google, Microsoft, and AWSYahoo Finance · Nov 3, 2026Healthcare stocks are on their biggest hot streak in a generation. Think twice before chasing the rally.MarketWatch · Oct 28, 2026Is USA Rare Earth Stock a Once-in-a-Generation Reshoring Opportunity?Yahoo Finance · Oct 22, 2026How Nvidia's OpenShell is securing the next generation of AI agents: Jensen HuangYahoo Finance · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Generation Bio
Is Generation Bio a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Generation Bio AI analysis
What does Generation Bio do?
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. It is in Biotechnology.
Who are Generation Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Generation Bio's.
Prices: daily closes to Feb 10, 2026. Fundamentals: company reports via invest-like data.